Comparison of Skin Thickness Under Treatment With Pimecrolimus 1% Cream, Hydrocortisonacetat 1% Cream, Betamethasonvalerat 0,1% Cream and Clobetasol-17-propionat 0,05% Cream Assessed by Optical Coherence Tomography (OCT) and 20-MHZ Ultrasound

• Status: Completed
• Trial end date: 2008-10-01
• Target enrollment: 0
• Participant gender: All

Summary

to compare the atrophogenic potentials of pimecrolimus 1% cream, hydrocortisonacetat 1% cream, betamethasonvalerat 0,1% cream and clobetasol-17-Propionat 0,05% cream

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Technische Universität Dresden
• Treatments: Clobetasol; Pimecrolimus; Tacrolimus

Criteria

Inclusion Criteria:

• male and female probands age between 18-40 years

• skin healthy

• skintype I-III according to Fitzpatrick

Exclusion Criteria:

• women of childbearing potential without adequate contraception

• pregnant or breastfeeding

• genetic defect of epidermal barrier

• external or systemic treatment with drugs, which probably have an effect to the thickness of skin or to the production of teleangiektasien within the last 6 month before study entry

• skin disease, which hinder the evaluation with OCT, ultrasound or dermaphot

• UV treatment within the last 4 weeks before study entry

• participation to another clinical trial within the last 30 days before study entry

• allergy against pimecrolimus or hydrocortison or betamethasonvalerat or Clobetasol-17-propionat

• severe systemic diseases; ongoing immunosuppressive treatment

• planned vaccination should realize before study entry or 28 days after end of treatment